Literature DB >> 17229041

A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma.

S Aburuz1, L G Heaney, J Millership, J Gamble, J McElnay.   

Abstract

AIM: To examine the relationship between cortisol suppression and asthma symptoms in patients with difficult asthma.
METHODS: Patients, referred to a specialist difficult asthma service and who fulfilled the criteria for difficult asthma, were recruited to the study in a sequential, unselected manner. At each clinic visit, all patients completed a validated asthma control questionnaire. For measuring cortisol suppression, early morning urinary cortisol [corrected for creatinine to give urinary cortisol creatinine ratio (UCC ratio)] was used. The urine samples were collected and stored at -70 degrees C until ready for analysis. Urinary cortisol was extracted (solid-phase extraction) and analysed using high-performance liquid chromatography. The Pearson correlation coefficient was used for correlation analysis while t-tests were used for between-group differences for normally distributed data. If the data were not normally distributed, nonparametric statistics were used. A P-value < 0.05 was considered statistically significant.
RESULTS: During the study period all the patients who attended the difficult asthma clinic and fulfilled the criteria for difficult asthma (n = 66) agreed to take part in the study. There were moderate to strong and significant associations between several measures of asthma control and UCC ratio. The correlation coefficient with five indicators of asthma control ranged between 0.3 and 0.5 (P < 0.05).
CONCLUSIONS: We have demonstrated a relationship between cortisol suppression and asthma control in difficult asthmatics on high-dose steroid therapy. We have proposed a model based on the relationship between symptom control and cortisol suppression, whereby both adherence and therapeutic adjustments could potentially be made. A properly controlled prospective clinical trial should examine the utility of this approach in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229041      PMCID: PMC2000719          DOI: 10.1111/j.1365-2125.2006.02745.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society.

Authors:  K F Chung; P Godard; E Adelroth; J Ayres; N Barnes; P Barnes; E Bel; P Burney; P Chanez; G Connett; C Corrigan; J de Blic; L Fabbri; S T Holgate; P Ind; G Joos; H Kerstjens; P Leuenberger; C G Lofdahl; S McKenzie; H Magnussen; D Postma; M Saetta; S Salmeron; P Sterk
Journal:  Eur Respir J       Date:  1999-05       Impact factor: 16.671

2.  Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.

Authors:  D J Clark; B J Lipworth
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

3.  Improved determination of urinary cortisol and cortisone, or corticosterone and 11-dehydrocorticosterone by high-performance liquid chromatography with ultraviolet absorbance detection.

Authors:  M Hay; P Mormède
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-11-21

4.  Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.

Authors:  D J Clark; A Grove; R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

5.  Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment.

Authors:  A M Wilson; E J Sims; B J Lipworth
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

6.  Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity.

Authors:  J C Pruessner; O T Wolf; D H Hellhammer; A Buske-Kirschbaum; K von Auer; S Jobst; F Kaspers; C Kirschbaum
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

7.  Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.

Authors:  B J Lipworth
Journal:  Arch Intern Med       Date:  1999-05-10

8.  Measurement of plasma prednisolone level to evaluate a prednisone treatment failure in an adolescent with Crohn's disease.

Authors:  D E Milov; M Hill; J M Andres; H A Cynamon; L Hendeles
Journal:  J Pediatr Gastroenterol Nutr       Date:  1989-04       Impact factor: 2.839

9.  Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens.

Authors:  H D McIntyre; C A Mitchell; S D Bowler; J G Armstrong; J A Wooler; D M Cowley
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

10.  Simple liquid chromatography method for the rapid simultaneous determination of prednisolone and cortisol in plasma and urine using hydrophilic lipophilic balanced solid phase extraction cartridges.

Authors:  S AbuRuz; J Millership; L Heaney; J McElnay
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-12-25       Impact factor: 3.205

View more
  1 in total

Review 1.  Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review.

Authors:  Fahad Alahmadi; Adam Peel; Brian Keevil; Rob Niven; Stephen J Fowler
Journal:  Clin Exp Allergy       Date:  2020-11-27       Impact factor: 5.018

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.